Treating Adults at Risk for Weight Gain With Interactive Technology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity represents a chronic disease associated with significant cardiovascular disease (CVD) morbidity and mortality. Weight gain in young adults adversely impacts the development of CVD risk factors. Further, there is a clear relationship between weight loss in obese persons and reduction in these CVD risk factors. Unfortunately, young adults are at high risk for weight gain. Although the scientific literature contains a number of reports regarding successful weight loss efficacy studies, young adults are typically underrepresented.

Cigarette smoking is the leading preventable cause of morbidity and mortality, but quitting smoking frequently results in significant weight gain. Proactive tobacco quit lines using behavioral smoking cessation interventions combined with nicotine replacement therapy (NRT) have been shown to help persons quit smoking. However, concerns about post-cessation weight gain have been reported as a significant barrier to quitting for many smokers particularly young adults.

If an efficacious behavioral weight loss program could be combined with an efficacious behavioral smoking cessation program that prevented or significantly attenuated post-cessation weight gain, then a large public health benefit may result. Such a combined weight loss/ weight gain prevention / smoking cessation program that used targeted intervention strategies to young adults, removed barriers to participation, and utilize interactive technology should be appealing to this age group. To date such a combined program has not been tested in young adult cigarette smokers. Therefore, the objective of this clinical trial is to develop and test a behavioral weight loss / weight gain prevention intervention delivered through interactive technology that can be used in conjunction with an efficacious tobacco quit line. A total of 330 participants will be necessary to adequately address the following specific aims.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment

NCT01889082

Obesity

COMPLETED NA

Motivational Interviewing for Weight Loss With Young Adults

NCT01899625

Obesity

COMPLETED NA

A Technology-Based Intervention for the Reduction of Overweight and Obesity Among College Students

NCT02196012

Overweight and Obesity

COMPLETED NA

Impact of Self-Monitoring Technology and Interventionist Contact on Weight Loss

NCT01999244

Overweight Obesity

COMPLETED NA

Strategies to Reduce Weight Gain in Hypertensive Smokers

NCT00119821

Cardiovascular Diseases Heart Diseases Hypertension +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Body Weight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tobacco Quitline Group

Group Type ACTIVE_COMPARATOR

Smoking Cessation

Intervention Type BEHAVIORAL

All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).

Tobacco Quitline plus Interactive Technology Group

Group Type EXPERIMENTAL

Smoking Cessation plus Weight Loss

Intervention Type BEHAVIORAL

All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Smoking Cessation

All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).

Intervention Type BEHAVIORAL

Smoking Cessation plus Weight Loss

All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

1. \*18 to 35 years old
2. BMI \> 22 kg / m2
3. Self report smoking \> 10 cigarettes each day
4. Have access to a telephone and the internet
5. Demonstrate ability to access a specific web site
6. Demonstrate ability to receive and respond to email
7. Willing to accept random assignment
8. \*Intending to be available for a 24 month intervention
9. \*At risk for weight gain (e.g. plan to quit smoking)

Persons will be excluded from the TARGIT study for the following:

1. \*Current participation in a commercial weight loss program (e.g. Weight Watchers, Jenny Craig, etc.), current use of a prescription weight loss medication, planned weight loss surgery within the next 24 months (e.g. gastric bypass, lap band, or liposuction), current or planned enrollment in another diet / physical activity / weight loss study
2. Currently meet recommendations for physical activity (i.e., 30 minutes or more of moderate physical activity per day on the majority of days each week - 150 minutes or more each week)
3. \*History of cerebral, coronary, or peripheral vascular disease, or serious uncontrolled cardiac arrhythmia, revascularization procedure or uncontrolled congestive heart failure in the past 6 months
4. Current substance abuse (includes alcohol use in excess of 21 drinks a week)
5. Uncontrolled hypertension as defined as BP \> 140/90 mm Hg
6. Presence of an unstable psychiatric condition or use of anti-psychotic drugs
7. History of significant kidney disease or liver disease
8. History of uncontrolled thyroid disease or pheochromocytoma
9. Current use of a medication that may interfere with primary study endpoints (e.g. a weight loss medication such as Orlistat, etc) or that may increase the risk of side effects from the study intervention that can not be discontinued
10. Severe uncontrolled asthma, bronchitis, or emphysema that precludes exercise
11. Resting heart rate \> 100
12. \*Malignancy in the last 5 years (except non-melanoma skin cancer)
13. Plans to move from the Memphis metropolitan area in the next two years
14. Current participation in another clinical trial
15. \*Other medical or behavioral factors, that in the judgment of the Principal Investigator, may interfere with study participation or the ability to follow the intervention protocol
16. \*History of diabetes treated with a medication that may cause hypoglycemia such as insulin or an oral hypoglycemic agent
17. Known allergy or sensitivity to the nicotine patch
18. \*Currently pregnant or gave birth within the last 6 months, currently lactating or breast feeding within the last 3 months, actively planning pregnancy within the next 24 months
19. \*BMI \< 18.5 kg / m2 or \> 40 kg / m2
20. \*Have a household member on study staff
21. \*Current treatment for an eating disorder
22. \*Unable to provide informed consent
23. \*Regular use of a systemic steroids defined as taking the medication most days of the week
24. \*Use of medications to treat attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes